ImmVirX develops receptor-targeted oncolytic viruses for cancer treatment, focusing on prevalent cancer types with limited treatment options.

ImmVirX

ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect.  The company is developing a bio-selected RNA virus to induce tumour inflammation and achieve immune cell infiltration via the RIG-I pathway. The targets for this approach are Ovarian, Head & Neck and those indications which present with liver metastases such as Colorectal, Hepatocellular carcinoma and Pancreatic cancer. The approach includes combination therapy with Immune Checkpoint Inhibitors and CAR-T agents using bio-selected RNA virus.
The company founders, Malcolm McColl and Prof. Darren Shafren, were Managing Director and CSO of Viralytics, an ASX listed oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million.  The ImmVirX team includes key management and researchers from Viralytics and is based at the former Viralytics laboratory facilities in Newcastle Australia.

Great update on our clinical program by CEO Malcolm McColl and CSO Darren Shafren on Oncology for the Inquisitive Mind Podcast. Thank you to the team for inviting us on to share our recent progress.

ImmVirX has presented an update showing promising signals in its Phase 1a/b study targeting solid cancers at the MOGA Annual Meeting.   IVX037 has been well tolerated, with signs of monotherapy activity, in particular in late-stage colorectal cancer patients: https://buff.ly/3Mac4Mw

ImmVirX is pleased to have CSO Darren Shafren and Medical Director Oksana Zdanska attending the 2024 Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting this week. 

An update from the phase 1a monotherapy trial of our lead candidate, IVX037 will be provided in a Poster presentation from Dr Jia (Jenny) Liu on 15th August. A Phase 1b featuring IVX037 in combination with Innovent's checkpoint inhibitor TYVYT will commence in the coming months.

ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl's presentation at The Bell Potter Securities Healthcare Conference 2023 is now available.

Click here to view the presentation: https://lnkd.in/gpQxeAH7

We are pleased to announce the appointment of Dr Oksana Zdanska as Medical Director, commencing today: https://buff.ly/49y35hH

Dr. Zdanska is a highly regarded clinical leader with extensive experience in clinical trials, including drug development of novel treatments. She has know-how and familiarity with cutting edge technologies including the use of oncolytic immunotherapies in clinical settings.

We are pleased to share a replay of CEO & Acting Chairman Dr Malcolm McColl's presentation at the NWR Virtual Healthcare Conference.

Shareholders and other interested parties can view the presentation at: https://buff.ly/3PLzXfE

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 4, 2024 5:03 AM	b1545f02
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 4, 2024 5:05 AM	bf73c279
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Sep 4, 2024 5:03 AM	f74bc294
translate crunchbase fundingrounds	general
peers	general	Sep 4, 2024 5:03 AM	cf918be2
news basic	general	Sep 4, 2024 5:03 AM	aa96cace
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

IMMV

COM:IMMVIRX

ImmVirX